IPD Analytics publishes a semi-annual Drug Pipeline and Trend Impact Report. The report identifies new brands, generics, and biosimilars across over 40 therapeutic areas. Around the same time, our Executive Pharmacy Team records a podcast episode to discuss the drugs with ongoing Phase III clinical trials or upcoming PDUFA dates that will have the greatest impact over the coming months.
Listen to highlights from the most recent podcast and view a sample of our report including 2020 Key Approvals to Watch and disease class overviews of Multiple Sclerosis and Migraine.
DRUG PIPELINE & TREND IMPACT REPORT & WEBINAR SERIES
